Cancers, Vol. 11, Pages 98: Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

In conclusion, our preclinical data support the hypothesis that treatment with afatinib might be a promising novel therapeutic strategy for CRC patients experiencing intrinsic and acquired cetuximab resistance.

Source: Cancers - January 15, 2019 Category: Cancer & Oncology Authors: Ines De Pauw Filip Lardon Jolien Van den Bossche Hasan Baysal Patrick Pauwels Marc Peeters Jan Baptist Vermorken An Wouters Tags: Article Source Type: research